Research

5/7/19

The Hunter James Kelly Research Institute (HJKRI) has received more than $2 million in National Institutes of Health (NIH) funding, enabling researchers to pursue a new approach to Krabbe disease.

3/12/19

The Jacobs School of Medicine and Biomedical Sciences is among 72 sites nationwide that are recruiting patients for a 12-week, randomized, placebo-controlled drug trial for the first treatment designed to benefit patients with mild-to-moderate Lewy body dementia (LBD).

3/4/19

Thirty-four original research projects from aspiring physician-scientists were on display at the 2019 Medical Student Research Forum.

3/1/19

Students from laboratories affiliated with the Genetics, Genomics and Bioinformatics graduate program (GGB) shared their findings during the fifth annual GGB Research Day.

2/15/19

Research by Gil I. Wolfe, MD, UB Distinguished Professor and Irvin and Rosemary Smith Chair of the Department of Neurology, shows that surgery to remove the thymus gland in patients with myasthenia gravis (MG) provides significant clinical benefits for as long as five years after the procedure.

12/18/18

New stem cell research led by Fraser J. Sim, PhD, associate professor of pharmacology and toxicology, has identified novel therapeutic targets for the treatment of multiple sclerosis (MS) and other inflammatory diseases.

10/11/18

Research by John J. Leddy, MD, clinical assistant professor of orthopaedics, and Barry S. Willer, PhD, professor of psychiatry, did not find evidence of early-onset dementia (EOD) in a study of retired National Football League and National Hockey League players.

8/27/18

Research led by Fraser J. Sim, PhD, associate professor of pharmacology and toxicology, has identified a new drug target for remyelination in multiple sclerosis (MS).

8/3/18

Researchers at the Hunter James Kelly Research Institute (HJKRI) have been awarded a pair of grants for the investigation of mechanisms underlying axonal degeneration in certain neurological disorders.